Table 2 Summary of characteristics identified from included studies reporting PANSS score
Characteristics categories | Stratifications | Study ID | Study design | Sample size | PANSS score (mean ± SD) |
|---|---|---|---|---|---|
Prior treatment with OAP | Risperidone (RIS) | Schreiner 2014 [44] | Pre-post trial (NCT01281527) | 191 | Baseline: 70.8 ± 15.1; Endpoint: 56.9 ± 17.3; Change: -13.9 ± 14.8 |
Si 2016 [45] | Pre-post trial (NCT01685931) | 263 | Baseline: 91.8 ± 12.4; Change: -31.0 ± 18.4 | ||
Sliwa 2011 [29] | Post hoc RCT (NCT00590577) | 106 | Baseline: 87.95 ± 12.13; Change: -16.62 ± 22.33 | ||
Olanzapine (OLA) | Schreiner 2014 [44] | Pre-post trial (NCT01281527) | 87 | Baseline: 71.4 ± 13.2; Endpoint: 62.3 ± 19.6; Change: -9.1 ± 17.5 | |
Si 2016 [45] | Pre-post trial (NCT01685931) | 52 | Baseline: 87.7 ± 12.5; Change: -25.5 ± 20.0 | ||
Aripiprazole (ARI) | Schreiner 2014 [44] | Pre-post trial (NCT01281527) | 46 | Baseline: 74.7 ± 14.9; Endpoint: 62.6 ± 16.5; Change: -12.2.± 16.7 | |
Paliperidone extended-release (Pali ER) | Schreiner 2014 [44] | Pre-post trial (NCT01281527) | 104 | Baseline: 71.3 ± 14.3; Endpoint: 60.4 ± 17.2; Change: -10.8 ± 14.4 | |
Paliperidone | Magliocco 2020 [40] | Observational study | 12 | Baseline: 98.33 ± 15.01; Endpoint-Mean: 72.626 | |
Quetiapine (QUE) | Schreiner 2014 [44] | Pre-post trial (NCT01281527) | 44 | Baseline: 70.8 ± 13.1; Endpoint: 60.5 ± 20.1; Change: -10.2 ± 19.6 | |
Other (chlorpromazine, haloperidol, penfluridol, perphenazine, sulpiride, aripiprazole, ziprasidone, amisulpride, quetiapine fumarate, amisulpride, clozapine) | Si 2016 [45] | Pre-post trial (NCT01685931) | 293 | Baseline: 92.4 ± 12.5; Change: -31.7 ± 20.4 | |
Ethnicity | Asia-Pacific region patients | Zhang 2015 [48] | Pre-post trial (NCT01051531) | 521 | Baseline: 64.1 ± 19.09; Change: -11.3 ± 21.38 |
Asian patients | Li 2016 [38] | Pre-post trial (NCT01527305) | 212 | Baseline: 90.0 ± 17.41; Change: -23.9 ± 23.24 | |
Chinese Patients | Zhang 2015 [46] | Pre-post trial (NCT01051531) | 108 | Baseline: 67.6 ± 18.44; Change: -15.3 ± 20.76 | |
Si 2016 [45] | Pre-post trial (NCT01685931) | 608 | Baseline: 91.74 ± 12.43; Change: -30.87 ± 19.48 | ||
Stage of disease | Acute Patients | Schreiner 2014 [36] | Pre-post trial (NCT01281527) | 212 | Baseline: 98.5 ± 20.1; LOCF Endpoint: 67.4 ± 24.0; Change: -31.0 ± 29.0 |
Li 2016 [38] | Pre-post trial (NCT01527305) | 212 | Baseline: 90.0 ± 17.41; Change: -23.9 ± 23.24 | ||
Sliwa 2011 [29] | Post hoc RCT (NCT00590577) | 106 | Baseline: 87.95 ± 12.13; Change: -16.62 ± 22.33 | ||
Si 2016 [45] | Pre-post trial (NCT01685931) | 608 | Baseline: 91.74 ± 12.43; Change: -30.87 ± 19.48 | ||
Stable Patients | Schreiner 2014 [35] | Pre-post trial (NCT01281527) | 589 | Baseline: 71.45 ± 14.53; Endpoint: 59.75 ± 17.99; Change: -11.76 ± 15.63 | |
Schreiner 2014 [43] | Pre-post trial (NCT01281527) | 593 | Baseline: 71.5 ± 14.6; Change: -11.7 ± 15.9; LOCF Endpoint: 59.7 ± 18.1 | ||
Duration of illness | ≤5 years | Li 2016 [47] | Pre-post trial (NCT01527305) | 88 | Baseline: 90.6 ± 14.04; Change: -30.0 ± 20.84 |
Zhang 2015 [48] | Pre-post trial (NCT01051531) | 521 | Baseline: 64.1 ± 19.09; Change: -11.3 ± 21.38 | ||
>5 years | Li 2016 [47] | Pre-post trial (NCT01527305) | 124 | Baseline: 89.5 ± 19.49; Change: -19.6 ± 20.99 | |
≤3 years | Schreiner 2014 [35] | Pre-post trial (NCT01281527) | 231 | Baseline: 72.6 ± 14.8; Endpoint: 57.5 ± 16.9; Change: -15.1 ± 15.6* | |
>3 years | Schreiner 2014 [35] | Pre-post trial (NCT01281527) | 358 | Baseline: 70.7 ± 14.4; Endpoint: 61.2 ± 18.7; Change: -9.6 ± 15.7* | |
>3 years vs ≤3 years | Li 2018 [24] | Pre-post trial (Multivariate analysis) | NR | PANSS<70: Odds Ratio (95%CI): 0.56 (0.34-0.92), p<0.0211* | |
Reason for switching PP1M | Switched for Lack of Efficacy | Schreiner 2014 [43] | Pre-post trial (NCT01281527) | 144 | Baseline: 80.3 ± 11.3; Change: -12.1 ± 15.1; LOCF Endpoint: 68.2 ± 17.0 |
Switched for Other Reasons | Schreiner 2014 [43] | Pre-post trial (NCT01281527) | 449 | Baseline: 68.6 ± 14.4; Change: -11.6 ± 16.2; LOCF Endpoint: 57.0 ± 17.6 | |
Time of start injection of PP1M | ≤1 week | Li 2016 [37] | Observational study | 121 | Baseline: 89.1 ± 14.99; Change: -26.4 ± 19.38* |
>1 week | Li 2016 [37] | Observational study | 91 | Baseline: 91.1 ± 20.21; Change: -20.6 ± 27.31* | |
PANSS total score at baseline | Continuous measures | Li 2018 [24] | Pre-post trial (Multivariate analysis) | NR | PANSS<70: Odds Ratio (95%CI): 0.91 (0.88-0.93), p<0.0001* |